Fortaleza Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Fortaleza Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,180	Closed	-$138K	–	167
2017 Q1	$138K	Sell	3,180 -85	-3%	-$3.64K	0.28%	113
2016 Q4	$126K	Hold	3,265	–	–	0.27%	114
2016 Q3	$165K	Buy	3,265 +85	+3%	+$4.23K	0.23%	79
2016 Q2	$145K	Sell	3,180 -1,620	-34%	-$74.6K	0.12%	85
2016 Q1	$190K	Hold	4,800	–	–	0.12%	93
2015 Q4	$272K	Sell	4,800 -120	-2%	-$6.1K	0.16%	73
2015 Q3	$196K	Sell	4,920 -1,800	-27%	-$87K	0.14%	105
2015 Q2	$321K	Buy	6,720 +3,070	+84%	+$130K	0.19%	93
2015 Q1	$145K	Buy	+3,650	New	+$131K	0.08%	156

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fortaleza Asset Management's NBIX Position: Q2 2017 in Review

Fortaleza Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2017, closing a stake of 3,180 shares — an estimated $138K sold.

Fortaleza Asset Management first reported a position in NBIX in Q1 2015 and held it in 9 quarters. The position peaked at $321K in Q2 2015. 221 funds tracked by Wall St. Rank hold NBIX as of Q2 2017.

Fortaleza Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2017 after selling out during the quarter.
Fortaleza Asset Management sold 3,180 Neurocrine Biosciences shares in Q2 2017, an estimated $138K.
Fortaleza Asset Management first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 9 quarters.
Fortaleza Asset Management's Neurocrine Biosciences position peaked at $321K in Q2 2015.
221 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2017.

Based on Fortaleza Asset Management's 13F filing for Q2 2017, filed 4 Aug 2017.